Pricopi Ciprian, Mordant Pierre, Rivera Caroline, Arame Alex, Foucault Christophe, Dujon Antoine, Le Pimpec Barthes Françoise, Riquet Marc
Department of General Thoracic Surgery, Georges Pompidou European Hospital, Descartes University, Paris, France.
Department of General Thoracic Surgery, Cedar Surgical Centre, Bois Guillaume, France.
Interact Cardiovasc Thorac Surg. 2015 Mar;20(3):316-21. doi: 10.1093/icvts/ivu417. Epub 2014 Dec 8.
We examined whether the changes in clinical practice with time correlated with the changes in the 90-day mortality following pneumonectomy.
The clinical records of consecutive patients undergoing pneumonectomy in two French centres from 1980 to 2009 were prospectively collected. The 90-day postoperative course was retrospectively studied according to clinical characteristics, underlying diseases, type of surgery and time-period (1980-1989; 1990-1999 or 2000-2009).
Pneumonectomy was performed in 2064 patients (right n = 948, males n = 1758, mean age 60 ± 10 years). Indications were non-small-cell lung cancer (n = 1805, 87%), mesothelioma (n = 39, 1.8%), other tumours (n = 132, 6.3%) and non-tumour disease (n = 88, 4.2%). The 30- and 90-day mortality were 17.4 and 7.2% in the first decade, 22.3 and 9% in the second decade and 26.4 and 7.3% in the third decade, respectively. In multivariate analysis, older age, right-sided resection, T3-T4 and N2 lung cancer disease were significantly associated with increased overall 90-day mortality, whereas surgery during the last decade was associated with a better outcome when compared with the first decade (RR: 0.63, 95% confidence interval: 0.50-0.80, P = 0.045). When focusing on patients with non-small-cell lung cancer (NSCLC), the 90-day mortality following induction therapy and pneumonectomy decreased from 21.9% in the 1980s to 8.2% in the 2000s (P = 0.038), while such decrease was not found in patients without induction therapy or in patients undergoing a lobectomy.
The overall 90-day mortality after pneumonectomy was not significantly modified over the last 30 years, while the 90-day mortality after induction therapy followed by pneumonectomy for NSCLC decreased significantly.
我们研究了临床实践随时间的变化是否与肺切除术后90天死亡率的变化相关。
前瞻性收集了1980年至2009年在法国两个中心接受肺切除术的连续患者的临床记录。根据临床特征、基础疾病、手术类型和时间段(1980 - 1989年;1990 - 1999年或2000 - 2009年)对术后90天的病程进行回顾性研究。
2064例患者接受了肺切除术(右肺切除948例,男性1758例,平均年龄60±10岁)。手术指征为非小细胞肺癌(1805例,87%)、间皮瘤(39例,1.8%)、其他肿瘤(132例,6.3%)和非肿瘤性疾病(88例,4.2%)。第一个十年的30天和90天死亡率分别为17.4%和7.2%,第二个十年分别为22.3%和9%,第三个十年分别为26.4%和7.3%。多因素分析显示,年龄较大、右侧切除、T3 - T4期和N2期肺癌与90天总体死亡率增加显著相关,而与第一个十年相比,最后一个十年进行的手术预后更好(风险比:0.63,95%置信区间:0.50 - 0.80,P = 0.045)。聚焦于非小细胞肺癌(NSCLC)患者,诱导治疗后肺切除术后的90天死亡率从20世纪80年代的21.9%降至21世纪00年代的8.2%(P = 0.038),而在未接受诱导治疗的患者或接受肺叶切除术的患者中未发现这种下降。
在过去30年中,肺切除术后总体90天死亡率没有显著改变,而NSCLC诱导治疗后肺切除术后的90天死亡率显著下降。